Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.51 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11683055 | 0.91 | PLA2G4B (0.61) | PLA2G4BPTGS1KDM4ELMNAALDH1A1 | |
| SCHEMBL1586362 | 0.88 | PLA2G4B (0.50) | PLA2G4BPTGS1AKR1C3AKR1C2KDM4E | |
| SCHEMBL874241 | 0.86 | POLB (0.54) | KDM4EPOLBLMNAALDH1A1L3MBTL1 | |
| SCHEMBL7339995 | 0.85 | PLA2G4B (0.62) | PLA2G4BPTGS1LMNAALDH1A1LTB4R | |
| SCHEMBL11684213 | 0.85 | PLA2G4B (0.69) | PLA2G4BKDM4ELMNAALDH1A1TBXAS1 | |
| SCHEMBL10076458 | 0.84 | KDM4E (0.47) | PLA2G4BKDM4ELMNAALDH1A1L3MBTL1 | |
| SCHEMBL17508211 | 0.84 | TBXAS1 (0.52) | KDM4ELMNATBXAS1CYP1A2CYP2D6 | |
| SCHEMBL10076459 | 0.84 | ALDH1A1 (0.55) | KDM4ELMNAALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL1443020 | 0.84 | LMNA (0.70) | PLA2G4BKDM4ELMNAALDH1A1TBXAS1 | |
| SCHEMBL1285778 | 0.84 | PLA2G4B (0.77) | PLA2G4BKDM4ELMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116496658-B | Crystalline amorphous hybrid zinc oxide nanoparticle ink, preparation method and application | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-07-02 | — | — | CN | claimed |
| CN-116496658-A | Crystalline amorphous hybrid zinc oxide nanoparticle ink, preparation method and application | 中国科学院苏州纳米技术与纳米仿生研究所 | 2023-07-28 | — | — | CN | claimed |
| CN-116496658-B | Crystalline amorphous hybrid zinc oxide nanoparticle ink, preparation method and application | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-07-02 | — | — | CN | disclosed |
| CN-116496658-A | Crystalline amorphous hybrid zinc oxide nanoparticle ink, preparation method and application | 中国科学院苏州纳米技术与纳米仿生研究所 | 2023-07-28 | — | — | CN | disclosed |
| CN-108863850-B | Biaryl compound and preparation method and application thereof | 复旦大学 | 2021-05-18 | — | — | CN | disclosed |
| US-10844017-B2 | Biaryl compound, preparation method and use thereof | FUDAN UNIVERSITY (CN) | 2020-11-24 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| WO-2008112440-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | PLA2G4B 556/4885PTGS1 853/4885AKR1C3 4225/4885 |
| US-10844017-B2 | Biaryl compound, preparation method and use thereof | RORC, RORB, RORA | PLA2G4B 3725/4885PTGS1 2527/4885AKR1C3 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.